Невсасывающиеся (кишечные) антибактериальные препараты в гастроэнтерологии: спектр применения рифаксимина

1. Белоусова Е.А., Никитина Н.В., Мишуровская Т.С., Златкина А.Р. Возможности препаратов на основе микробных метаболитов для восстановления кишечной микробиоты. Consilium Medicum 2005: 9–13.
2. Болезни печени и желчевыводящих путей. Руководство для врачей. Под ред. В.Т.Ивашкина. М.: ООО «Издат. дом М Вести», 2002.
3. Бондаренко В.М., Матулевич Т.В. Дисбактериоз кишечника как клинико-лабораторный синдром: современное состояние проблемы. Руководство для врачей. М.: ГЭОТАР-Медиа, 2007.
4. Ефименко Н.А., Базаров А.С.Антимикробная терапия интраабдоминальных инфекций (По материалам рекомендаций Североамериканского общества по хирургическим инфекциям). Клин. микроб. и антимикроб. химиотер. 2003; 5 (2): 5–14.
5. Яковенко Э.П., Иванов, А.Н., Казарина А.В. и др. Нарушение нормального состава кишечных бактерий: клиническое значение и вопросы терапии. РМЖ. 2008; 10 (2): 41–6.
6. Almy TP, Howell DA. Diverticular disease of colon. Eng J Med 1980; 302: 324–31
7. Bresadola F, Intini S, Anania G et al. Chemoterapeutic prophilaxis in the preparation of the large intestine for surgical interventions:rifaximin P.O. vs cephalosporini I.V. Ann Ital Chir 1992; 63: 201–7.
8. De Gastro R, Domenichelli V, Di Lorenzo FP et al. Rifaximin treatmemnt for acute recurrent diarrhea in children with genitourinary disorders. Curr Ther Res 1998; 59: 746–52.
9. Descombe JJ, Dubourg D, Picard et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14: 51–6.
10. Di Stefano M, Strocchi AS, Malservisi S et al. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000; 14: 1001–8.
11. Di Stefano M, Malservisi S, Veneto G et al. Rifaximini versus chlortetracycline in the short-term treftment of small intestine bacterial overgrowth. Aliment Pharmacol Thtr 2000; 14: 551–6.
12. DuPont HL, Ericsson CD, Mathewson JJ et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 1998; 59: 708–14.
13. DuPont HL, Ericsson CD, Mathewson JJ et all. Rifaximin for treatment of travelerer's diarrhea:A randomized doubleblind clinical trial versus ciprofloxacin. Clin Infect Dis 2001; 33: 1807–15.
14. DuPont HL. Community-acquired diarrheal disease in western countries: applications of nonabsorbable oral antibiotic therapy. Adv Stud Med 2003; 3 (suppl A): S945–S950.
15. Gionchett P, Rizello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment; a double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220–1.
16. Gruttadauria G, Barbera, Gutaia G, Salanitri G. Prevention of infection in colonic surgery by rifaximin. A controlled prospective , randomized trial. Eur Rev Med Pharmacol Sci 1987; 9: 101–5.
17. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity – a review. Chemotherapy. 2005; 51 (suppl. 1): 67–72.
18. King CE, Tosces PP. Small intestine bacterial overgrowth. Gastroenterology 1979; 76: 1035–55.
19. Latella G, Pimpo MT, Sottili S et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 55–62.
20. Li E, Stanley SL Jr. The role of newer antibiotics in gastroenterology. Gastroenterol Clin North Am 1992; 21: 613–29.
21. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852–8.
22. Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: An open label study. Gastroenterology 2002; 122 (suppl. 1): 434.
23. Rizello MF, Venturi A et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs. mesalamine. Gastroenterology 2000; 118: 781.
24. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non absorbable rifamicin for the treatment of the hepatic encephalopathy. A double-blind, randomized trial. Curr Med Res Opin 1997; 13: 593–601.
25. Papi C, Ciaco A, Koch M et al. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre doubleblind placebo-controlled trial. Aliment Pharmacol Ther 1995; 9: 33–9.
26. Plantera C, Zannjni F, Scribano ML et al. An antibiotic regimen for the treatment of active Crohn's disease: A randomized controlled clinicaltrial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328–32.
27. Rizello F, Gionchetti P, Venturi A et al. Rifaximin systemic absorbtion in patients with ulcerative colitis. Eur J Clin Pharmacol 1998; 54: 91–3.
28. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Bacterial flora in digestive disease. Focus on rifaximin. Eds. С Scarpignato, A. Lanas. Basel: Karger, 2006; 15–39.
29. Veradi S,Veradi V, Fusillo M. Rifaximin effectiveness evaluation in the preparetijn of large intestine to surgery. Eur Rev Med Pharmacol Sci 1986; 8: 267–70.
30. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12: 203–8.